Asian Pacific Journal of Allergy and Immunology

  • HOME
  • ABOUT
  • EDITORS
  • SUBMISSION
    • Online Submission
    • Author Instructions
  • ISSUE
    • Current
    • Early Online
    • Archives
  • PERMISSIONS
  • CONTACT
  • ADVERTISE
Home
 / 
Original Article
 / 
Effect of inhaled corticosteroids on bone mineral density in patients with asthma

May 18, 2020
Original Article

Effect of inhaled corticosteroids on bone mineral density in patients with asthma

Hiroyoshi Watanabe,1 Kumiya Sugiyama,1,3 Naotatsu Otsuji,1 Kentaro Nakano,1 Hajime Arifuku,1 Tomoshige Wakayama,1 Shingo Tokita,1 Kenya Koyama,1 Hirokuni Hirata,1 Masafumi Arima,2 Kazuhiro Kurasawa,2 Yasutsugu Fukushima1

Affiliations:
1 Department of Respiratory Medicine and Clinical Immunology Dokkyo Medical University, Saitama Medical Center, Japan
2 Department of Rheumatology, Dokkyo Medical University, Japan
3 National Hospital Organization, Utsunomiya National Hospital, Japan

Abstract

Background: Inhaled corticosteroids (ICS) are a safe treatment for asthma. However, at higher doses, ICS use has been reported to inhibit adrenocortical function.
Objective: This study aimed to evaluate the effect of ICS on bone mineral density (BMD) in adult patients with asthma.
Methods: Ultrasonic bone densitometry was performed in 40 patients (14 men, 26 women, mean age 61.2 years, mean duration of asthma 6.19 years) who were receiving ICS for asthma, and the whole bone density, thickness of cortical bone, and density of cancellous bone of the radius was measured. The age-matched mean was set as 100%. Lifetime cumulative dose of ICS was calculated using all past prescriptions.
Results: No significant correlations were observed between lifetime cumulative ICS dose and whole bone density (r2 = 0.011), cortical bone thickness (r2 = 0.022), and cancellous bone density (r2 = 0.004). No significant differences were observed between lower and higher lifetime cumulative ICS dose among these BMD parameters (104% vs 97%, 103% vs 99%, and 106% vs 91%, respectively). No significant correlations or differences in lifetime cumulative ICS dose were observed by asthma severity, asthma duration, and pulmonary function. Also, serum markers of bone metabolism showed no significant correlations or differences with lifetime cumulative ICS dose.
Conclusions: In the entire study population, long-term ICS use was safe and was not associated with an increased risk of osteoporosis.
Key words: Asthma, Bone mineral density, Inhaled corticosteroids (ICS), Osteoporosis, Safety,

Full Text
Vol. 41, No. 1
Asthma, Bone mineral density, Inhaled corticosteroids (ICS), Osteoporosis, safety

Categories

  • Announcement (1)
  • Case Report (23)
  • Early Online (93)
  • Original Article (223)
  • Review Article (29)

Key words

allergen Allergic rhinitis Allergy Anaphylaxis Asthma atopic dermatitis child Children Chlorhexidine chronic rhinosinusitis chronic spontaneous urticaria Chronic Urticaria COVID-19 cytokine depression diagnosis drug allergy Drug hypersensitivity efficacy Epidemiology food allergy Food hypersensitivity house dust mite IgE Immunotherapy obstructive sleep apnea Omalizumab prevalence primary immunodeficiency Quality of life Questionnaire Reliability risk factor risk factors safety SARS-CoV-2 Sensitization Severe asthma Skin prick test Specific IgE Thai treatment urticaria vaccine Vitamin D
Asian Pacific Journal of Allergy and Immunology

Support Contact

Managing Editor
Ms. Patrawadee Pitakpolrat
E-mail: managingeditor@apjai-journal.org

Production Editor
Ms. Chanita Jangsawang
E-mail: chanita.j@apjai-journal.org

Asian Pacific Journal of Allergy and Immunology © 2025 All rights reserved.
All rights reserved | Privacy Policy